Cannabis and Your Heart: Inside the MARY-JANE Trial Studying THC and Arrhythmias

As cannabis potency climbs and consumption becomes mainstream, a critical question has gone largely unanswered: what does THC actually do to your heart rhythm? A pioneering clinical trial at the University of California, San Francisco is working to find out, and its early findings are raising important considerations for the estimated 52 million Americans who use cannabis.

The MARY-JANE Cannabis and Heart Rhythm Trial represents one of the first rigorous, randomized studies designed to measure whether inhaled cannabis directly increases the frequency of abnormal heartbeats. With THC concentrations in commercial products now regularly exceeding 30 percent — and some infused pre-rolls topping 60 percent — the cardiovascular implications of modern cannabis use may be fundamentally different from those studied in prior decades.

How the MARY-JANE Trial Works

The UCSF study uses an elegant case-crossover design. Participants are randomly instructed to either consume or avoid inhaled cannabis on assigned days during a 14-day monitoring period. Throughout the study, each participant wears three devices simultaneously: an external heart monitor that continuously tracks cardiac rhythm, a glucose monitor that measures metabolic changes, and a fitness tracker that records step counts, sleep patterns, and physical activity.

This multi-sensor approach allows researchers to capture a comprehensive picture of how cannabis affects the cardiovascular system in real-world conditions, not just in a sterile lab environment. By having each participant serve as their own control — comparing their cannabis days against their abstention days — the study controls for individual differences in baseline health, genetics, and lifestyle.

The trial is registered on ClinicalTrials.gov under identifier NCT06021613 and is actively enrolling participants in the San Francisco Bay Area.

What Existing Research Shows About Cannabis and Heart Rhythm

The MARY-JANE trial did not emerge in a vacuum. A growing body of observational research has linked cannabis use to increased cardiovascular risk, though the evidence has been complicated by confounding factors like tobacco co-use, varying THC potencies, and differences in consumption methods.

A comprehensive 2025 meta-analysis published in Heart Rhythm Journal examined data from large population-based studies and found that cannabis users had a 71 percent increased risk of atrial arrhythmias compared to non-users. Atrial fibrillation, the most common sustained arrhythmia, was particularly associated with regular cannabis consumption.

A separate review published in Heart Rhythm O2 provided a mechanistic explanation for these findings. Delta-9-tetrahydrocannabinol, the primary psychoactive component of cannabis, causes sympathetic nervous system stimulation and endothelial dysfunction — the lining of blood vessels stops working properly. At the cellular level, THC affects cardiomyocyte ion channels, extends the repolarization phase of the cardiac cycle, and modifies autonomic control. Together, these effects create a biological foundation for arrhythmogenesis, the abnormal generation of heartbeat rhythms.

The review noted that cannabis-induced cardiac arrhythmias can range from relatively benign premature atrial contractions to potentially dangerous ventricular tachycardia, though severe events remain uncommon in the general population.

Why This Research Matters Now

The urgency behind studies like MARY-JANE stems from a fundamental mismatch between cannabis market realities and the scientific evidence base. Today's cannabis products deliver THC concentrations that would have been unimaginable 20 years ago. Flower routinely tests above 25 percent THC, concentrates exceed 80 percent, and the fastest-growing product category — infused pre-rolls — is pushing boundaries with offerings above 60 percent THC.

Meanwhile, most of the existing cardiovascular research on cannabis was conducted with products containing 3 to 10 percent THC. The dose-response relationship between modern high-potency cannabis and cardiac risk is essentially uncharted territory.

Additionally, cannabis is increasingly being used by older adults, a demographic with higher baseline risk for atrial fibrillation and other cardiac events. Data from the National Survey on Drug Use and Health shows that cannabis use among adults over 65 has increased more than tenfold since 2007. Many of these users are managing chronic conditions with cannabis while also taking cardiovascular medications, creating potential interaction risks that have barely been studied.

What Consumers Should Know Right Now

Researchers emphasize that the existing evidence does not establish that cannabis definitively causes arrhythmias in otherwise healthy individuals. The association between cannabis and cardiac rhythm disturbances is statistically significant but does not equal causation — especially given the limitations of observational data.

However, several practical recommendations have emerged from the literature. Individuals with pre-existing heart conditions, particularly those with a history of atrial fibrillation or other arrhythmias, should discuss cannabis use with their cardiologist before consuming THC products. The method of consumption matters: inhaled cannabis (smoking and vaping) produces more rapid cardiovascular effects than edibles or tinctures, potentially creating sharper spikes in heart rate and blood pressure.

Dose also appears to be a factor. The available evidence suggests that lower-dose THC consumption carries less cardiovascular risk than high-potency products, though the precise threshold has not been established. Consumers who experience palpitations, rapid heartbeat, or chest discomfort after cannabis use should seek medical evaluation rather than dismissing these symptoms.

The Bigger Picture for Cannabis Science

The MARY-JANE trial is part of a broader wave of rigorous cannabis research that has been enabled by shifting federal policy. For decades, Schedule I classification made it extraordinarily difficult for researchers to conduct the kind of randomized, controlled studies that modern medicine relies on. As rescheduling to Schedule III progresses, the research pipeline is expected to accelerate significantly.

UCSF is not alone in pursuing cardiovascular cannabis research. Multiple academic medical centers across the University of California system are running cannabis clinical trials in 2026, covering topics from pain management to cognitive function. The collective output of these studies over the next few years will fundamentally reshape our understanding of how cannabis interacts with the human body.

For the cannabis community, the takeaway is not alarm but informed engagement. Understanding the cardiovascular dimensions of cannabis use allows consumers to make better decisions about products, dosing, and consumption methods — exactly the kind of evidence-based approach that the legal cannabis industry needs to mature responsibly.

Key Takeaways

• The UCSF MARY-JANE trial is the first randomized study tracking real-time cardiac rhythm changes during cannabis use, with participants wearing heart monitors for 14 consecutive days
• A meta-analysis found cannabis users face a 71 percent increased risk of atrial arrhythmias, though causation has not been established
• THC affects heart cells by disrupting ion channels, extending repolarization, and stimulating the sympathetic nervous system
• Consumers with pre-existing heart conditions should consult a cardiologist before using THC products, especially high-potency inhaled formats

Explore cannabis news, find dispensaries, and join the community at Budpedia.